Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dose Ranging Study In Phase III Could Bolster Rx Safety Profile, Temple Says

Executive Summary

Evaluating a range of doses in Phase III clinical trials could bolster the safety profile for an investigational new agent, FDA Office of Medical Policy Director Robert Temple, MD, said April 9

You may also be interested in...



Clinical Trials Should Include Finding Maintenance Dose, FDA’s Temple Says

Maintenance doses are not sufficiently studied in clinical trials, FDA Center for Drug Evaluation & Research Medical Policy Director Robert Temple, MD, said

Clinical Trials Should Include Finding Maintenance Dose, FDA’s Temple Says

Maintenance doses are not sufficiently studied in clinical trials, FDA Center for Drug Evaluation & Research Medical Policy Director Robert Temple, MD, said

Approval Delays For Standard NMEs Caused Primarily By “Safety Issues” – FDA

FDA is citing "safety issues" as the primary reason for approval delays for standard new molecular entities in 2000 and 2001 in its 12002 Report to the Nation

Related Content

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel